TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22083887

Group type: EXPERIMENTAL
Intervention: BWA‐LCAP (Bodyweight adjusted leukocytapheresis)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine 3,000 mL LCAP
Number of subjects: 28
Study: 19111212

Group type: EXPERIMENTAL
Intervention: Single-row technique (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Double-row technique (group 2)
Number of subjects: 80
Study: 16723422

Group type: EXPERIMENTAL
Intervention: Habit reversal (HR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 25
Study: 15073160

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) at a dosage of 300-500 mg/kg (most commonly 400 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 5
Study: 11319684

Group type: EXPERIMENTAL
Intervention: HPV-11 L1 VLP vaccine
Number of subjects: 0
Study: 9141913

Group type: EXPERIMENTAL
Intervention: ACEI-treated patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not treated with ACEIs)
Number of subjects: 18
Study: 8431574

Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma (PPP), n = 12
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), n = 12
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no APP), n = 12
Number of subjects: 36
Study: 2446080

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin (0.15 mg/kg)
Number of subjects: 10
Study: 29861437

Group type: EXPERIMENTAL
Intervention: PM2.5 level averaged over 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PM2.5 level averaged over 10 days
Number of subjects: 16
Study: 27466602

Group type: EXPERIMENTAL
Intervention: Soy-dairy protein blend (PB) supplementation (22 g daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) isolate supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Isocaloric maltodextrin (MDP) placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combined PB and WP treatments
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All treatments (PB, WP, MDP)
Number of subjects: 68
Study: 25017822

Group type: EXPERIMENTAL
Intervention: SMS assessments+feedback (SA+F)
Number of subjects: 765

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 765

Group type: COMPARATOR
Intervention: SMS assessments (SA)
Number of subjects: 765
Study: 22690981

Group type: EXPERIMENTAL
Intervention: Postdischarge care transition (PDCT) program
Number of subjects: 333

Group type: COMPARATOR
Intervention: Regular discharge process (control)
Number of subjects: 333
Study: 20202095

Group type: EXPERIMENTAL
Intervention: Acrylic-based resilient liner (ARL)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional acrylic resin (CAR)
Number of subjects: 74
Study: 18547727

Group type: EXPERIMENTAL
Intervention: Escitalopram 20mg once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 15647413

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. extract (150 mL yielding 62.6 mg of cyanidin‐3‐sambubioside, 81.6 mg of delphinidin‐3‐sambubioside, and 147.4 mg of total anthocyanins)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. extract
Number of subjects: 6
Study: 12003051

Group type: EXPERIMENTAL
Intervention: Standard Error of Measurement (SEM)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Asthma Quality of Life Questionnaire (AQLQ)
Number of subjects: 198
Study: 10862852

Group type: EXPERIMENTAL
Intervention: Laminaria
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) gel (0.5 microg every 6 hours for two doses followed by oxytocin if indicated)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 321
Study: 9089422

Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) intravenous administration (50 mg and 100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) oral administration (100 mg and 200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 450 mg oral dose of AZT-P-ddI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) oral administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) oral and intravenous administration
Number of subjects: 12
Study: 8478959

Group type: EXPERIMENTAL
Intervention: 0.5 g/m2 DFMO every day (step 3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.125, 0.25, 0.5, or 0.75 g/m2 DFMO four times a day (step 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.125 or 0.25 g/m2 four times a day or 0.5 or 1.0 g/m2 every day (step 2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5 g/m2 DFMO every day
Number of subjects: 32
Study: 3090945

Group type: EXPERIMENTAL
Intervention: Pulsed yellow tunable dye laser (577-nm wavelength)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Argon laser
Number of subjects: 3

Group type: COMPARATOR
Intervention: Carbon dioxide laser
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pulsed yellow dye laser
Number of subjects: 3
Study: 29739994

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 322154

Group type: EXPERIMENTAL
Intervention: Hip Circumference (HC)
Number of subjects: 322154

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 322154

Group type: EXPERIMENTAL
Intervention: Waist-Hip Ratio (WHR)
Number of subjects: 322154

Group type: EXPERIMENTAL
Intervention: BMI-adjusted HC and WC
Number of subjects: 322154

Group type: EXPERIMENTAL
Intervention: Central adiposity (WHR)
Number of subjects: 322154
Study: 27128958

Group type: EXPERIMENTAL
Intervention: Minocycline (50 mg twice per day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24452704

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection at the proximal 2/10 and 3/10 of calf length
Number of subjects: 40

Group type: COMPARATOR
Intervention: Botulinum toxin A injection at and below the midbelly of the muscle (Control)
Number of subjects: 40
Study: 22157067

Group type: EXPERIMENTAL
Intervention: MRI-guided treatment decision (group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI-blinded treatment decision (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different injection than proposed by independent physician (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection correlated with imaging (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall decision making effect of MRI
Number of subjects: 0
Study: 19758580

Group type: EXPERIMENTAL
Intervention: Lifestyle weight loss intervention (LW)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 300
Study: 18190829

Group type: EXPERIMENTAL
Intervention: Continuous bladder irrigation
Number of subjects: 80

Group type: COMPARATOR
Intervention: No bladder irrigation (control)
Number of subjects: 80
Study: 16183781

Group type: EXPERIMENTAL
Intervention: Propiverine 15 mg twice daily for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12817154

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 1088
Study: 11291023

Group type: EXPERIMENTAL
Intervention: Psychopharmacologic treatment for hypersexuality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical algorithm for treatment
Number of subjects: 0
Study: 8704114

Group type: EXPERIMENTAL
Intervention: Low-flux biocompatible membrane
Number of subjects: 159

Group type: COMPARATOR
Intervention: Low-flux bioincompatible membrane
Number of subjects: 159
Study: 31711417

Group type: EXPERIMENTAL
Intervention: Ephedrine 20 mg (E group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Phenylephrine 250 mcg (P group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (C group)
Number of subjects: 70
Study: 29463484

Group type: EXPERIMENTAL
Intervention: Interactive nursing skills mobile application
Number of subjects: 66

Group type: COMPARATOR
Intervention: Noninteractive nursing video contents
Number of subjects: 66
Study: 26606274

Group type: EXPERIMENTAL
Intervention: Assessment of Motor and Process Skills (AMPS) motor scale
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Assessment of Motor and Process Skills (AMPS) process scale
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-rater reliability for AMPS motor scale
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-rater reliability for AMPS process scale
Number of subjects: 30
Study: 23801545

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 143
Study: 22154131

Group type: EXPERIMENTAL
Intervention: Home-based intervention consisting of 4 tailored newsletters and 2 motivational phone calls
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group receiving 4 children's books
Number of subjects: 43
Study: 18721085

Group type: EXPERIMENTAL
Intervention: Free and Easy Wanderer Plus (FEWP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 16648333

Group type: EXPERIMENTAL
Intervention: Video-feedback interactional treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive counseling (Control)
Number of subjects: 80
Study: 12732774

Group type: EXPERIMENTAL
Intervention: Closed suction (Jackson-Pratt) drains
Number of subjects: 164

Group type: COMPARATOR
Intervention: No drains
Number of subjects: 164
Study: 10926346

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination product (SFC) 50/250 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide 800 microg twice daily
Number of subjects: 0
Study: 9187592

Group type: EXPERIMENTAL
Intervention: Pressure-triggered pressure-support ventilation at 75% ventilatory support
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flow-triggered pressure-support ventilation at 75% ventilatory support
Number of subjects: 16
Study: 1526015

Group type: COMPARATOR
Intervention: Phosphoramidon (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: UK 79300 (100 mg, twice daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: UK 79300 (25 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2868640

Group type: EXPERIMENTAL
Intervention: 1.0 mg tablet of Ea-0643 (group-A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.5 mg tablet of Ea-0643 (group-B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo tablet (group-C)
Number of subjects: 56
Study: 29193471

Group type: EXPERIMENTAL
Intervention: Quantitative assessment-based nursing intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Regular nursing (control group)
Number of subjects: 184
Study: 27978537

Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP followed by MVA ME-TRAP (prime-boost vaccination)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anti-rabies vaccine (control group)
Number of subjects: 120
Study: 23962321

Group type: EXPERIMENTAL
Intervention: Real rTMS combined with CIMT
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham rTMS combined with CIMT
Number of subjects: 19
Study: 22976514

Group type: EXPERIMENTAL
Intervention: Low level laser therapy applied with output power of 100 mW in continuous mode with sweeping motion.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with no laser energy applied (only brought into position).
Number of subjects: 100
Study: 21044723

Group type: COMPARATOR
Intervention: Wheelchair tilt-in-space at 35° with 100° recline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Wheelchair tilt-in-space at 15°, 25°, and 35° with 120° recline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Wheelchair tilt-in-space at 15° and 25°
Number of subjects: 11
Study: 18607726

Group type: EXPERIMENTAL
Intervention: Community and school-based anti-violence media intervention ('Resolve It, Solve It')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16644631

Group type: EXPERIMENTAL
Intervention: 5 mg muraglitazar
Number of subjects: 1159

Group type: COMPARATOR
Intervention: 30 mg pioglitazone
Number of subjects: 1159
Study: 14585016

Group type: EXPERIMENTAL
Intervention: Phase shifts of feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Period shifts of pitch contents for synchronized feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined phase and period shifts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All feedback conditions in the same session
Number of subjects: 0
Study: 10657761

Group type: EXPERIMENTAL
Intervention: Topical capsaicin (CAP) 0.05% liniment applied 3 times daily for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo substance (vehicle)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical capsaicin (CAP)
Number of subjects: 10
Study: 8928705

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 U/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 100 U/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 1510019

Group type: EXPERIMENTAL
Intervention: Guided breathing retraining
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Guided breathing retraining with physiologic monitoring of thoracic and abdominal movement plus peripheral temperature
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Guided breathing retraining with physiologic monitoring of thoracic and abdominal movement, peripheral temperature and end‐tidal carbon dioxide
Number of subjects: 41

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 41
Study: 6208603

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 75
Study: 31100050

Group type: EXPERIMENTAL
Intervention: Single Lactobacillus rhamnosus GG (Culturelle, 20 billion live organisms) instillation
Number of subjects: 10
Study: 31032742

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (MicroLaserPeel™ and ProFractional™)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control side (untreated)
Number of subjects: 19
Study: 30481882

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2a for 48 weeks
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2a for 96 weeks
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2a for 48 weeks and 96 weeks
Number of subjects: 303
Study: 27316780

Group type: EXPERIMENTAL
Intervention: Intervention promoting fruit and vegetable consumption (F/V) via a videogame
Number of subjects: 400
Study: 24684829

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 119
Study: 22426952

Group type: EXPERIMENTAL
Intervention: Morning teriparatide (20 μg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Evening teriparatide (20 μg daily)
Number of subjects: 50
Study: 20722561

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/day) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stable dose of ACEIs and/or ARBs
Number of subjects: 40
Study: 18755192

Group type: EXPERIMENTAL
Intervention: High salivary testosterone levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low salivary testosterone levels
Number of subjects: 0
Study: 15864242

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 71
Study: 12755652

Group type: EXPERIMENTAL
Intervention: History of suicide attempts
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: History of sexual abuse, lack of confidant prior to illness onset, more prior hospitalizations for depression, suicidal thoughts when depressed, and cluster B personality disorder
Number of subjects: 648
Study: 10773129

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernioplasty (TAPP)
Number of subjects: 176
Study: 8633952

Group type: EXPERIMENTAL
Intervention: 21-mm HP St. Jude Medical valve
Number of subjects: 66

Group type: COMPARATOR
Intervention: 21-mm standard valve
Number of subjects: 66

Group type: COMPARATOR
Intervention: 23-mm standard valve
Number of subjects: 66
Study: 1333741

Group type: EXPERIMENTAL
Intervention: Lysine-aspirin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3001610

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 55
Study: 30573499

Group type: EXPERIMENTAL
Intervention: Topical brimonidine tartrate 0.15% administered 20 min prior to injection
Number of subjects: 58

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 58
Study: 30695661

Group type: EXPERIMENTAL
Intervention: Lapatinib and Trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29136445

Group type: EXPERIMENTAL
Intervention: 250 μg peanut patch
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 100 μg peanut patch
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 50 μg peanut patch
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 250 μg peanut patch (6-11 years)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 250 μg peanut patch (adolescents/adults)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: All groups (TEAEs)
Number of subjects: 221
Study: 25935227

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Transesophageal echocardiogram (TEE)
Number of subjects: 122
Study: 23855376

Group type: EXPERIMENTAL
Intervention: Web-based guided stress-management training based on problem solving and emotion regulation.
Number of subjects: 264

Group type: COMPARATOR
Intervention: Waitlist control group for six months.
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Web-based guided stress-management training.
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis from a societal perspective.
Number of subjects: 264
Study: 21737951

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 63
Study: 19362316

Group type: EXPERIMENTAL
Intervention: QTinno
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Global
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Tangent
Number of subjects: 1422
Study: 16300723

Group type: EXPERIMENTAL
Intervention: Acceptance group (listened to a rationale for accepting emotions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Suppression group (listened to a rationale for suppressing emotions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acceptance group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 15027519

Group type: EXPERIMENTAL
Intervention: Lactic acid 12% and pramoxine hydrochloride 1% cream applied twice daily for 7 days
Number of subjects: 24
Study: 11309549

Group type: EXPERIMENTAL
Intervention: Lotrafiban (5-100 mg, twice daily for 12 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lotrafiban (exposure > 835 ng.h/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lotrafiban (lower dose recommendation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9203727

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based IgM capture ELISA
Number of subjects: 224

Group type: COMPARATOR
Intervention: Neutralization assay
Number of subjects: 224
Study: 8498378

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure
Number of subjects: 23

Group type: COMPARATOR
Intervention: No nasal continuous positive airway pressure
Number of subjects: 23
Study: 3320366

Group type: EXPERIMENTAL
Intervention: Flupenthixol 0.5 mg twice daily
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg twice daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 29695262

Group type: EXPERIMENTAL
Intervention: Homeopathic H. perforatum in a potentisation of C200
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27113931

Group type: EXPERIMENTAL
Intervention: MRI + (PM or DTI)
Number of subjects: 114

Group type: COMPARATOR
Intervention: MRI + NE
Number of subjects: 114
Study: 25005834

Group type: EXPERIMENTAL
Intervention: 1,000 IU/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 2,000 IU/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study: 23106759

Group type: EXPERIMENTAL
Intervention: Maintenance First (8-week stability skills maintenance module followed by a 20-week behavioral weight-loss program)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Weight Loss First (20-week behavioral weight-loss program followed by an 8-week problem-solving skills maintenance module)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Maintenance First
Number of subjects: 267

Group type: COMPARATOR
Intervention: Weight Loss First
Number of subjects: 267
Study: 20413383

Group type: EXPERIMENTAL
Intervention: Personal bone density information via dual‐energy X‐ray absorptiometry (DXA)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 196
Study: 18854910

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) after mitoxantrone induction (20 mg/d SC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) after mitoxantrone induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) alone (20 mg/d SC)
Number of subjects: 40
Study: 17081391

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal septal myocardial ablation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Subaortic ventriculotomy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 37
Study: 12922120

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus toxoid-acellular pertussis vaccine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 97
Study: 10342425

Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of 2.5% prilocaine and 2.5% lidocaine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose topical capsaicin (1%)
Number of subjects: 9